EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

NKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression

Sophie Curio iD, Sarah C Edwards, Toshiyasu Suzuki, Jenny McGovern, Chiara Triulzi, Nagisa Yoshida, Gustav Jonsson iD, Teresa Glauner, Damiano Rami, Robert Wiesheu, Anna Kilbey, Rachel Violet Purcell und 2 weitere

Discovery Immunology · 2022

DOI: 10.1093/discim/kyac002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discovery Immunology, 2022. Verfasst von Sophie Curio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Imperial College London, London, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust, Breast Cancer Now, Wellcome Trust RCDF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

γδT cells are unconventional T cells particularly abundant in mucosal tissues that play an important role in tissue surveillance, homeostasis, and cancer. γδT cells recognize stressed cells or cancer cells through the NKG2D receptor to kill these cells and maintain normality. Contrary to the well-established anti-tumor function of these NKG2D-expressing γδT cells, we show here that, in mice, NKG2D regulates a population of pro-tumor γδT cells capable of producing IL-17A. Germline deletion of Klrk1, the gene encoding NKG2D, reduced the frequency of γδT cells in the tumor microenvironment and delayed tumor progression. We further show that blocking NKG2D reduced the capability of γδT cells to produce IL-17A in the pre-metastatic lung and that co-culture of lung T cells with NKG2D ligand-expressing tumor cells specifically increased the frequency of γδT cells. Together, these data support the hypothesis that, in a tumor microenvironment where NKG2D ligands are constitutively expressed, γδT cells accumulate in an NKG2D-dependent manner and drive tumor progression by secreting pro-inflammatory cytokines, such as IL-17A.

Schlagwörter

Stichwörter der Autor:innen

NKG2Dinflammationtumor immunologyγδT cells

Autor:innen und Institutionen

  • Department of Life Sciences, Imperial College London, London, UK.
  • Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Cancer Research UK Beatson Institute, Glasgow, UK.
  • Department of Surgery, University of Otago, Christchurch, New Zealand.

ORCID-Profile: Sophie Curio, Gustav Jonsson, Seth B Coffelt, Nadia Guerra

Förderung

  • Wellcome Trust
  • Breast Cancer Now
  • Wellcome Trust RCDF
  • Stevenson Fund
  • Cancer Research UK Glasgow Centre
  • Marie Curie European Fellowship
  • Naito Foundation Grant for Research Abroad

Zitieren

APA

Curio, S., Edwards, S. C., Suzuki, T., McGovern, J., Triulzi, C., Yoshida, N., Jonsson, G., Glauner, T., Rami, D., Wiesheu, R., Kilbey, A., Violet Purcell, R., Coffelt, S. B., & Guerra, N. (2022). NKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression. Discovery Immunology. https://doi.org/10.1093/discim/kyac002

Vancouver

Curio S, Edwards SC, Suzuki T, McGovern J, Triulzi C, Yoshida N, et al. NKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression. Discovery Immunology. 2022. doi:10.1093/discim/kyac002

BibTeX
@article{Curio2022,
  author = {Curio, Sophie and Edwards, Sarah C and Suzuki, Toshiyasu and McGovern, Jenny and Triulzi, Chiara and Yoshida, Nagisa and Jonsson, Gustav and Glauner, Teresa and Rami, Damiano and Wiesheu, Robert and Kilbey, Anna and Violet Purcell, Rachel and Coffelt, Seth B and Guerra, Nadia},
  title = {NKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression},
  journal = {Discovery Immunology},
  year = {2022},
  doi = {10.1093/discim/kyac002}
}
Kostenlos starten →